The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084244 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Natalia Vasileva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences, Akad. Lavrentiev Ave, 8, Novosibirsk 63009…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Temozolomide, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian state-funded project for ICBFM SB RAS, Russian Science Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Virotherapy is one of the perspective technologies in the treatment of malignant neoplasms. Previously, we have developed oncolytic vaccinia virus VV-GMCSF-Lact and its high cytotoxic activity and antitumor efficacy against glioma was shown. In this work, using immortalized and patient-derived cells with different sensitivity to VV-GMCSF-Lact, we evaluated the cytotoxic effect of chemotherapy agents. Additionally, we studied the combination of VV-GMCSF-Lact with temozolomide which is the most preferred drug for glioma treatment. Experimental results indicate that first adding temozolomide and then the virus to the cells is inherently more efficient than dosing it in the reverse order. Testing these regimens in the U87 MG xenograft glioblastoma model confirmed this effect, as assessed by tumor growth inhibition index and histological analysis. Moreover, VV-GMCSF-Lact as monotherapy is more effective against U87 MG glioblastoma xenografts comparing temozolomide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences, Akad. Lavrentiev Ave, 8, Novosibirsk 630090, Novosibirsk Region, Russia.
- "Oncostar" LLC, Inzhenernaya Street 23, Novosibirsk 630090, Novosibirsk Region, Russia.
- The State Research Center of Virology and Biotechnology "VECTOR", Koltsovo 630559, Novosibirsk Region, Russia.
- Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Frunze Street 17, Novosibirsk 630091, Novosibirsk Region, Russia.
ORCID-Profile: Natalia Vasileva, Alisa Ageenko, Arina Byvakina, Aleksandra Sen'kova, Galina Kochneva, Sergey Mishinov, Elena Kuligina
Förderung
- Russian state-funded project for ICBFM SB RAS
- Russian Science Foundation
Zitieren
APA
Vasileva, N., Ageenko, A., Byvakina, A., Sen'kova, A., Kochneva, G., Mishinov, S., Richter, V., & Kuligina, E. (2024). The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084244
Vancouver
Vasileva N, Ageenko A, Byvakina A, Sen'kova A, Kochneva G, Mishinov S, et al. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084244
BibTeX
@article{Vasileva2024,
author = {Vasileva, Natalia and Ageenko, Alisa and Byvakina, Arina and Sen'kova, Aleksandra and Kochneva, Galina and Mishinov, Sergey and Richter, Vladimir and Kuligina, Elena},
title = {The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084244}
}
EUVIMED